Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model

Cancer cachexia is a multifactorial disease that causes continuous skeletal muscle wasting. Thereby, it seems to be a key determinant of cancer‐related death. Although anamorelin, a ghrelin receptor agonist, has been approved in Japan for the treatment of cachexia, few medical treatments for cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanada, Kako, Fukasawa, Kunpei, Hinata, Hiroki, Imai, Shú, Takayama, Kentaro, Hirai, Hideyo, Ohfusa, Rina, Hayashi, Yoshio, Itoh, Fumiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530881/
https://www.ncbi.nlm.nih.gov/pubmed/35849084
http://dx.doi.org/10.1111/cas.15491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530881/
https://www.ncbi.nlm.nih.gov/pubmed/35849084
http://dx.doi.org/10.1111/cas.15491

Ejemplares similares